Skip to main content
. 2013 Nov;9(11 Suppl 5):1–24.

Table 3.

Treatment Options for IBS-D

Improvements in Symptoms Grade* FDA-Approved for IBS-D?
Global Symptoms Pain Bloating Stool Frequency Stool Consistency
Alosetron + + + + 1B Yes
Antibiotics (rifaximin) + + 1B No
Antidepressants + + 1B No
Loperamide + + 2C No
Antispasmodics ± + 2C No
Probiotics (Bifidobacterial some combinations) + 2C No

FDA, US Food and Drug Administration; IBS-D, irritable bowel syndrome, diarrhea.

*

Recommendations are based on the balance of benefits, risks, burdens, and sometimes cost: Grade 1, strong; Grade 2, weak. Assessment of quality of evidence is according to the quality of study design, consistency of results among studies, directness, and applicability of study endpoints: Grade A, high; Grade B, moderate; grade C, low.

Adapted from ACG Task Force on IBS. Am J Gastroenterol. 2009;104(suppl 1):S1-S35.40